GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell ...
GSK plc, a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together, announced that the European Medicines Agency has granted Priority Medicines (PRIME) Designation for GSK’227, its B7-H3-targeted …